The weekly litigation news digest is live. Subscribe now

IP Verse

Apixaban Formulations - EP3781132

The patent EP3781132 was granted to Bristol Myers Squibb on Mar 20, 2024. The application was filed on Apr 15, 2019 under application number EP19722333A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3781132

BRISTOL MYERS SQUIBB
Application Number
EP19722333A
Filing Date
Apr 15, 2019
Status
Granted And Under Opposition
Feb 16, 2024
Publication Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
STADA ARZNEIMITTELDec 19, 2024KERNEBECKADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2012087978
DESCRIPTIONUS2013045245
DESCRIPTIONUS6967208
INTERNATIONAL-SEARCH-REPORTCN105663049
INTERNATIONAL-SEARCH-REPORTCN106913528
INTERNATIONAL-SEARCH-REPORTWO2014027334
OPPOSITIONWO2010003641
OPPOSITIONWO2011106478
OPPOSITIONWO2014052678

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents